MX2017009696A - Formas cristalinas de c21h22cl2n4o2. - Google Patents
Formas cristalinas de c21h22cl2n4o2.Info
- Publication number
- MX2017009696A MX2017009696A MX2017009696A MX2017009696A MX2017009696A MX 2017009696 A MX2017009696 A MX 2017009696A MX 2017009696 A MX2017009696 A MX 2017009696A MX 2017009696 A MX2017009696 A MX 2017009696A MX 2017009696 A MX2017009696 A MX 2017009696A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- c21h22ci2n
- sub
- isopropylaminopyridin
- pyrrole
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- NCBIFXNQFURYON-UHFFFAOYSA-N 4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxylic acid Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(O)=O)=C1Cl NCBIFXNQFURYON-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- KSERXGMCDHOLSS-UHFFFAOYSA-N n-[1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)NC(CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Removal Of Specific Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona formas cristalinas de un compuesto de fórmula (I). También se proporcionan composiciones farmacéuticas que incluyen las formas cristalinas que se proporcionan y métodos de uso de las formas cristalinas proporcionadas y composiciones farmacéuticas para el tratamiento de cáncer. Se ha descubierto que las formas cristalinas de la [1-(3-clorofenil)-2-hidroxietil]amida del ácido 4-(5-cloro-2-isopropilaminopiridin-4-il)-1H-pirrolo-2-carboxílico se pueden preparar, las cuales muestran propiedades mejoradas, por ejemplo estabilidad sorprendentemente mejorada y características de solubilidad mejorada. Así, la presente invención proporciona la [1-(3-clorofenil)-2-hidroxietil] amida del ácido 4-(5-cloro-2-isopropilaminopiridin-4-il)-1H-pirrolo-2-ca rboxílico cristalina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110449P | 2015-01-30 | 2015-01-30 | |
| PCT/US2016/015829 WO2016123574A1 (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017009696A true MX2017009696A (es) | 2017-10-23 |
Family
ID=56544441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009696A MX2017009696A (es) | 2015-01-30 | 2016-01-29 | Formas cristalinas de c21h22cl2n4o2. |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9676746B2 (es) |
| EP (1) | EP3250562A4 (es) |
| JP (4) | JP7258460B2 (es) |
| CN (2) | CN116854662A (es) |
| AU (4) | AU2016211246B2 (es) |
| CA (2) | CA2975048C (es) |
| HK (1) | HK1244274A1 (es) |
| MX (1) | MX2017009696A (es) |
| NZ (2) | NZ772411A (es) |
| SG (2) | SG11201705924RA (es) |
| WO (1) | WO2016123574A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116854662A (zh) | 2015-01-30 | 2023-10-10 | 生物医学谷探索股份有限公司 | C21H22Cl2N4O2的晶型 |
| WO2017129088A1 (zh) * | 2016-01-27 | 2017-08-03 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物的制备方法 |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| US20230024584A1 (en) * | 2019-11-20 | 2023-01-26 | University Of Kentucky Research Foundation | Anti-cancer compositions and methods |
| WO2023169480A1 (zh) * | 2022-03-08 | 2023-09-14 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| TW202400572A (zh) * | 2022-03-24 | 2024-01-01 | 美商生物醫學谷探索公司 | Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| EP0245357B1 (en) | 1985-10-23 | 1991-08-07 | The Upjohn Company | Angiostatic steroids |
| US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| EP0477195A1 (en) | 1989-06-16 | 1992-04-01 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| ES2187503T3 (es) | 1991-11-22 | 2003-06-16 | Alcon Lab Inc | Esteroides angiostaticos. |
| KR20010111298A (ko) | 2000-02-05 | 2001-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | Ｅｒｋ의 억제제로서 유용한 피라졸 조성물 |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| RU2376299C2 (ru) | 2004-05-14 | 2009-12-20 | Вертекс Фармасьютикалз, Инкорпорейтед | Пиррольные соединения в качестве ингибиторов erk протеинкиназ, их синтез и промежуточные соединения |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| PL2091910T3 (pl) | 2006-12-06 | 2015-02-27 | Conatus Pharmaceuticals Inc | Postacie krystaliczne kwasu (3S)-3-[N-(N’-(2-tert-butylofenylo)oksamylo)alaninylo]amino-5-(2’,3’,5’,6’-tetrafluorofenoksy)-4-oksopentanowego |
| CA3124804C (en) * | 2012-09-18 | 2023-08-22 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| CN116854662A (zh) | 2015-01-30 | 2023-10-10 | 生物医学谷探索股份有限公司 | C21H22Cl2N4O2的晶型 |
-
2016
- 2016-01-29 CN CN202310821608.XA patent/CN116854662A/zh active Pending
- 2016-01-29 CA CA2975048A patent/CA2975048C/en active Active
- 2016-01-29 AU AU2016211246A patent/AU2016211246B2/en active Active
- 2016-01-29 EP EP16744240.9A patent/EP3250562A4/en active Pending
- 2016-01-29 NZ NZ772411A patent/NZ772411A/en unknown
- 2016-01-29 NZ NZ734041A patent/NZ734041A/en unknown
- 2016-01-29 WO PCT/US2016/015829 patent/WO2016123574A1/en active Application Filing
- 2016-01-29 CN CN201680013774.5A patent/CN107406413A/zh active Pending
- 2016-01-29 CA CA3218488A patent/CA3218488A1/en active Pending
- 2016-01-29 SG SG11201705924RA patent/SG11201705924RA/en unknown
- 2016-01-29 MX MX2017009696A patent/MX2017009696A/es unknown
- 2016-01-29 SG SG10202101979TA patent/SG10202101979TA/en unknown
- 2016-01-29 JP JP2017539596A patent/JP7258460B2/ja active Active
- 2016-01-29 US US15/011,377 patent/US9676746B2/en active Active
-
2017
- 2017-05-17 US US15/598,181 patent/US10183927B2/en active Active
-
2018
- 2018-03-16 HK HK18103713.0A patent/HK1244274A1/zh unknown
- 2018-12-20 US US16/227,820 patent/US10738027B2/en active Active
-
2020
- 2020-03-31 JP JP2020063198A patent/JP2020100674A/ja active Pending
- 2020-07-07 US US16/922,365 patent/US11390600B2/en active Active
- 2020-10-20 AU AU2020257041A patent/AU2020257041C1/en active Active
-
2021
- 2021-12-01 JP JP2021195403A patent/JP2022033866A/ja active Pending
-
2022
- 2022-06-16 US US17/842,632 patent/US20220324832A1/en active Pending
- 2022-09-05 AU AU2022228084A patent/AU2022228084B2/en active Active
-
2023
- 2023-05-17 JP JP2023081553A patent/JP2023096080A/ja active Pending
- 2023-10-25 AU AU2023254937A patent/AU2023254937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017009696A (es) | Formas cristalinas de c21h22cl2n4o2. | |
| MD20160118A2 (ro) | Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1 | |
| MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
| PH12018500610A1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| MX2020002924A (es) | Lactamas fusionadas de arilo y heteroarilo. | |
| MX2015012431A (es) | Pirrol amida como inhibidores. | |
| WO2014031438A3 (en) | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | |
| MX2014012695A (es) | Derivados de isoindolona. | |
| PH12018500626A1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
| PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| EA202090413A1 (ru) | Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2015012111A (es) | Moduladores de ship1 y métodos relacionados con éstos. | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| MY191352A (en) | Aldosterone synthase inhibitors | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний | |
| PH12016502281A1 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors | |
| MA39993A (fr) | Dérivés de pyrrolidine -2,5-dione, compositions pharmaceutiques et procédés pour une utilisation en tant qu'inhibiteursde de ido1 | |
| UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази |